Tolerogenic Dendritic Cells and Negative Vaccination in Transplantation: from Rodents to Clinical Trials

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2012 Aug 22

PMID 22908013

Citations 34

Authors

Aurelie Moreau

Emilie Varey

Gaelle Beriou

Marcelo Hill

Laurence Bouchet-Delbos

Mercedes Segovia

Maria-Cristina Cuturi

Affiliations

Soon will be listed here.

Abstract

The use of immunosuppressive (IS) drugs to treat transplant recipients has markedly reduced the incidence of acute rejection and early graft loss. However, such treatments have numerous adverse side effects and fail to prevent chronic allograft dysfunction. In this context, therapies based on the adoptive transfer of regulatory cells are promising strategies to induce indefinite transplant survival. The use of tolerogenic dendritic cells (DC) has shown great potential, as preliminary experiments in rodents have demonstrated that administration of tolerogenic DC prolongs graft survival. Recipient DC, Donor DC, or Donor Ag-pulsed recipient DC have been used in preclinical studies and administration of these cells with suboptimal immunosuppression increases their tolerogenic potential. We have demonstrated that autologous unpulsed tolerogenic DC injected in the presence of suboptimal immunosuppression are able to induce Ag-specific allograft tolerance. We derived similar tolerogenic DC in different animal models (mice and non-human primates) and confirmed their protective abilities in vitro and in vivo. The mechanisms involved in the tolerance induced by autologous tolerogenic DC were also investigated. With the aim of using autologous DC in kidney transplant patients, we have developed and characterized tolerogenic monocyte-derived DC in humans. In this review, we will discuss the preclinical studies and describe our recent results from the generation and characterization of tolerogenic monocyte-derived DC in humans for a clinical application. We will also discuss the limits and difficulties in translating preclinical experiments to theclinic.

Citing Articles

Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.

Ma Y, Shi R, Li F, Chang H Cell Commun Signal. 2024; 22(1):262.

PMID: 38715122 PMC: 11075321. DOI: 10.1186/s12964-024-01641-7.

Transcriptomic Analysis Identifies A Tolerogenic Dendritic Cell Signature.

Robertson H, Li J, Kim H, Rhodes J, Harman A, Patrick E Front Immunol. 2021; 12:733231.

PMID: 34745103 PMC: 8564488. DOI: 10.3389/fimmu.2021.733231.

Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity.

Passeri L, Marta F, Bassi V, Gregori S Int J Mol Sci. 2021; 22(16).

PMID: 34445143 PMC: 8395087. DOI: 10.3390/ijms22168415.

The Role of Regulatory Myeloid Cell Therapy in Renal Allograft Rejection.

Zhuang J, Hou J Front Immunol. 2021; 12:625998.

PMID: 33717141 PMC: 7943475. DOI: 10.3389/fimmu.2021.625998.

Donor myeloid derived suppressor cells (MDSCs) prolong allogeneic cardiac graft survival through programming of recipient myeloid cells in vivo.

Cai S, Choi J, Borges T, Zhang H, Miao J, Ichimura T Sci Rep. 2020; 10(1):14249.

PMID: 32859934 PMC: 7455707. DOI: 10.1038/s41598-020-71289-z.

References

Yamano T, Watanabe S, Hasegawa H, Suzuki T, Abe R, Tahara H . Ex vivo-expanded DCs induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin grafts. Blood. 2011; 117(9):2640-8. DOI: 10.1182/blood-2010-07-293860. View

Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi M . Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation. 2005; 79(8):969-72. DOI: 10.1097/01.tp.0000158277.50073.35. View

Bonham C, Peng L, Liang X, Chen Z, Wang L, Ma L . Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002; 169(6):3382-91. DOI: 10.4049/jimmunol.169.6.3382. View

Min W, Gorczynski R, Huang X, Kushida M, Kim P, Obataki M . Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol. 1999; 164(1):161-7. DOI: 10.4049/jimmunol.164.1.161. View

Schwartz R . T cell clonal anergy. Curr Opin Immunol. 1997; 9(3):351-7. DOI: 10.1016/s0952-7915(97)80081-7. View

Yu G, Xu X, Vu M, Kilpatrick E, Li X . NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med. 2006; 203(8):1851-8. PMC: 2118385. DOI: 10.1084/jem.20060603. View

Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M, Ramo-Tello C, Pujol-Borrell R, Martinez-Caceres E . Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol. 2012; 42(3):771-82. DOI: 10.1002/eji.201141835. View

Probst H, Lagnel J, Kollias G, van den Broek M . Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity. 2003; 18(5):713-20. DOI: 10.1016/s1074-7613(03)00120-1. View

Lu L, Qian S, Hershberger P, Rudert W, Lynch D, Thomson A . Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol. 1997; 158(12):5676-84. View

10.

Correale P, Campoccia G, Tsang K, Micheli L, Cusi M, Sabatino M . Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer. 2001; 37(7):892-902. DOI: 10.1016/s0959-8049(01)00063-6. View

11.

Peche H, Trinite B, Martinet B, Cuturi M . Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant. 2005; 5(2):255-67. DOI: 10.1111/j.1600-6143.2004.00683.x. View

12.

Emmer P, van der Vlag J, Adema G, Hilbrands L . Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation. 2006; 81(10):1451-9. DOI: 10.1097/01.tp.0000208801.51222.bd. View

13.

Berger T, Schulze-Koops H, Schafer M, Muller E, Lutz M . Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS One. 2009; 4(8):e6645. PMC: 2721636. DOI: 10.1371/journal.pone.0006645. View

14.

Cheong C, Matos I, Choi J, Dandamudi D, Shrestha E, Longhi M . Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010; 143(3):416-29. PMC: 3150728. DOI: 10.1016/j.cell.2010.09.039. View

15.

Giannoukakis N, Bonham C, Qian S, Chen Z, Peng L, Harnaha J . Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther. 2000; 1(5 Pt 1):430-7. DOI: 10.1006/mthe.2000.0060. View

16.

Zahorchak A, Kean L, Tokita D, Turnquist H, Abe M, Finke J . Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation. 2007; 84(2):196-206. DOI: 10.1097/01.tp.0000268582.21168.f6. View

17.

Dudziak D, Kamphorst A, Heidkamp G, Buchholz V, Trumpfheller C, Yamazaki S . Differential antigen processing by dendritic cell subsets in vivo. Science. 2007; 315(5808):107-11. DOI: 10.1126/science.1136080. View

18.

Divito S, Wang Z, Shufesky W, Liu Q, Tkacheva O, Montecalvo A . Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood. 2010; 116(15):2694-705. PMC: 2974582. DOI: 10.1182/blood-2009-10-251058. View

19.

Li M, Zhang X, Zheng X, Lian D, Zhang Z, Ge W . Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol. 2007; 178(9):5480-7. DOI: 10.4049/jimmunol.178.9.5480. View

20.

Dhodapkar M, Steinman R . Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 2002; 100(1):174-7. DOI: 10.1182/blood.v100.1.174. View